Ni2o will use Nurosene’s NetraAI technology to accelerate their research into treatments for neurodegenerative diseases.
TorontoAnd November 29, 2021 / CNW / – Nurosene Health Inc. (“Nurosene” or “the Company”) (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a health technology company focused on building a generation of healthier minds, announced today that it has partnered with Ni2o, a company Oxford university Corporation, to utilize Nurosene’s NetraAI to support and accelerate research into treatments for neurodegenerative diseases.
Ni2o’s Kiwi wireless brain implant will leverage NetraAI’s patient mapping and computational power to provide more accurate treatment protocols for neurodegenerative diseases. Kiwi is able to interfere with damaged brain tissue using light and electrical pulses, and it has already shown amazing potential to develop into a real treatment protocol.
Ni2o was founded by Dr. Newton Howard, one of the world’s leading figures in neuroscience, who developed a revolutionary brain-computer interface (BCI) to treat a wide range of neurodegenerative brain disorders and improve cognitive performance. The famous brain and cognition scientist started this work in Oxford As Professor of Computational Neuroscience and Neurosurgery, then continued at Massachusetts Institute of Technology (Massachusetts Institute of Technology) where he was director of the Artificial Intelligence Laboratory as well as founding the Mind Machine project.
“Dr. Howard’s work in the field of deep brain stimulation (DBS) is exciting, and he clearly recognizes that the heterogeneity of debilitating brain diseases requires two things: a tool that can be customized for each person and a map that allows the tool to treat people with precision. Think of NetraAI as a navigational guidance system for this amazing technology. We have We already have maps of Alzheimer’s and ALS patients as part of our IP portfolio, and through this collaboration, our systems will get smarter,” said Dr. Joseph Gerassi, chief scientific officer of Nurosene.
Dr. Howard, CEO of Ni2o, is working on a new brain model that involves integrating electrical, optical and chemical properties. His leadership in this field has resulted in a way forward in treating Alzheimer’s, Parkinson’s and ALS patients with a minimally invasive procedure. Dr. Howard has spent more than 30 years developing advanced technology for companies such as Boeing, Intel, Google and Microsoft.
“Nurosene’s focus on brain health is perfectly aligned with Ni2o’s vision. Dr. Geraci and I have worked in the neurodegeneration research space for some time, where our work is supported by government organizations, including IARPA1. It is exciting to be partnered to access their machine learning platform NetraAI to increase our ability to adapt our own tools to these complex diseases. “Kiwi is at the forefront of technology and we are very excited about making an impact on human health,” said Dr. Howard.
Nurosene’s NetraAI technology is a self-generated artificial intelligence that has revealed precise insights into diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. NetraAI recently received an award for its work at ALS in a global challenge involving a robust genetic data set. These resulting maps are essential in order to develop treatments for these diseases as patients can be very different, despite having the same nomenclature.
1 IARPA, Intelligence Advanced Research Projects Activity, is an organization within the Office of the Director of National Intelligence responsible for leading research to overcome difficult challenges relevant to the United States intelligence community. IARPA characterizes its mission as follows: “Visualize and lead high-risk, high-return research that delivers innovative technology for an overwhelming future intelligence advantage.”
about dr. Newton Howard
Dr. Howard holds advanced degrees in mathematics (Oxford), Cognitive Informatics (Sorbonne), Neurosurgery (Oxford), and Doctor of Medical Sciences (Sorbonne). He has made significant contributions to the fields of neuroscience, linguistics, and national defense. Dr. Howard’s career spans academia, the US military, and the private sector. A prolific science author and inventor, he is highly skilled at moving research from the lab to military and commercial applications, including technology you might use every day like Siri, Wi-Fi hotspots, Skype, Google Earth and Google Translate.
Nurosene provides individuals with the tools and technology that enables them to take control of their mental health. Our mission is to build the next generation of better, healthier minds by taking advantage of technological advances in artificial intelligence. With our team of experts and partners, Nurosene is placed at the forefront of significant research and innovation, striving to disrupt traditional mental health treatments.
For more information, visit www.nurosene.com.
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation that is based on Nurosene’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information may be identified by the use of forward-looking terms such as “expect,” “likely,” “may,” “will,” “should,” “intend,” “anticipate,” “probable,” “suggest,” “estimate,” and words Other similar ones, including negative and grammatical variations of them, or statements that “certain events or circumstances” may, “will,” or “will,” or through strategic discussions. Forward-looking information includes estimates, plans, projections, opinions, forecasts, expectations, objectives, directions, or other statements that are not factual. Specifically, this press release contains forward-looking statements relating, among other things, to the company’s NetraMark subsidiary’s activities — including its NetraAI technology — in partnership with Ni2o and its technology, including Kiwi, as well as its growth and other initiatives.
Any forward-looking information speaks only as of the date it is provided, and except as required by law, Nurosene undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and Norusin cannot predict all of them. In considering these forward-looking statements, readers should bear in mind the risk factors and other cautionary statements in Nurosene’s final long-form dated prospectus. May 20 2021 It is filed with the relevant Canadian Securities Regulatory Authorities on SEDAR at www.sedar.com. Risk and other factors mentioned in Nurosene’s long definitive prospectus could cause actual events or results to differ materially from those described in any forward-looking information.
CSE is not responsible for the adequacy or accuracy of this version.
Source: Nurosene Health Inc.
For more information: Blake Sing, Chief Financial Officer, [email protected], (416) 859-8838; KCSA Strategic Communications: Walter Pinto, Managing Director, [email protected], (212) 896-1254